| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Triarachidin does not have a specific pharmacological target as it is an endogenous metabolite rather than a therapeutic drug. As a triacylglycerol, it is involved in lipid metabolism, energy storage, and fatty acid homeostasis. Its "target" in research is the metabolic pathways involving triglyceride synthesis, hydrolysis, and fatty acid metabolism.
|
|---|---|
| ln Vitro |
In vitro activity of Triarachidin is not evaluated as a bioactive compound. Its utility lies in its role as a metabolite and reference standard for lipidomics research. It can be used as a substrate for lipases and other lipid-metabolizing enzymes in enzymatic assays. Its "activity" is reflected in its chemical properties as a triglyceride and its role in lipid metabolism studies.
|
| ln Vivo |
In vivo, Triarachidin is an endogenous metabolite involved in lipid metabolism and energy storage. As a triglyceride, it is synthesized in the liver and adipose tissue and stored in lipid droplets. It is hydrolyzed by lipases to release free fatty acids for energy production. Its levels are studied in the context of metabolic disorders, obesity, and lipid metabolism.
|
| Enzyme Assay |
In vitro enzyme assays with Triarachidin typically involve studying lipases and other lipid-metabolizing enzymes. The compound is used as a substrate to measure enzyme activity. Standard assays involve incubating the triglyceride with enzyme preparations in appropriate buffers, and the release of free fatty acids is measured by colorimetric, fluorometric, or chromatographic methods.
|
| Cell Assay |
Trieicosanoate is not typically used in cell culture experiments as a bioactive compound. However, it may be employed in studies investigating lipid metabolism and triglyceride handling in cell lines such as adipocytes, hepatocytes, or macrophages. Cells are treated with the compound, and lipid accumulation, lipolysis, or gene expression changes are assessed. Its role is primarily as a model triglyceride for lipid research.
|
| Animal Protocol |
In vivo animal experiments with Triarachidin are not commonly performed as it is an endogenous metabolite. If used, it would be in studies of lipid metabolism, where the compound or its stable isotope-labeled analogs are administered to animals to study triglyceride absorption, distribution, metabolism, and excretion. These studies provide data on lipid handling and metabolic disorders.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of Triarachidin are consistent with those of dietary triglycerides. It is absorbed from the gastrointestinal tract after hydrolysis by lipases, reassembled into triglycerides in enterocytes, and transported in chylomicrons. It is distributed to tissues, stored in adipose tissue, or oxidized for energy. Its plasma half-life depends on the rate of clearance by lipoprotein lipase and tissue uptake.
|
| Toxicity/Toxicokinetics |
Toxicity Summary
It is safe at the current usage and concentration. Ingredient, concentration, and usage information can be found at: https://cir-reports.cir-safety.org Triarachidin has a low toxicity profile as it is a naturally occurring endogenous metabolite. As a triglyceride, it is a normal component of lipid metabolism and is generally safe at physiological concentrations. For research use, standard laboratory safety practices are sufficient. It is not classified as a hazardous substance. Comprehensive toxicology studies are not applicable as the compound is a natural metabolite. |
| Additional Infomation |
Triarachidin is an endogenous metabolite and a triacylglycerol composed of arachidic acid. It is used as a reference standard in lipidomics and metabolomics research. The compound is not a drug and has no clinical trials or therapeutic indications. It is available for laboratory research use only as a tool for studying lipid metabolism and as an analytical standard for lipid analysis.
|
| Molecular Formula |
C63H122O6
|
|---|---|
| Molecular Weight |
975.64
|
| Exact Mass |
974.924
|
| CAS # |
620-64-4
|
| PubChem CID |
522017
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
75-78ºC
|
| LogP |
21.109
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
62
|
| Heavy Atom Count |
69
|
| Complexity |
975
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC
|
| InChi Key |
KCVWRCXEUJUXIG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C63H122O6/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-46-49-52-55-61(64)67-58-60(69-63(66)57-54-51-48-45-42-39-36-33-30-27-24-21-18-15-12-9-6-3)59-68-62(65)56-53-50-47-44-41-38-35-32-29-26-23-20-17-14-11-8-5-2/h60H,4-59H2,1-3H3
|
| Chemical Name |
2,3-di(icosanoyloxy)propyl icosanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: < 1 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0250 mL | 5.1248 mL | 10.2497 mL | |
| 5 mM | 0.2050 mL | 1.0250 mL | 2.0499 mL | |
| 10 mM | 0.1025 mL | 0.5125 mL | 1.0250 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
